Púrpura de Henoch-Schönlein. Revisión de la literatura

  • Zoilo Morel Universidad Nacional de Asunción, Facultad de Medicina, Cátedra y Servicio de Pediatría, Asunción, Paraguay Servicio de Reumatología, Hospital Central del Instituto de Previsión Social, Asunción
  • Sonia Cabrera-Villalba Servicio de Reumatología, Hospital Central del Instituto de Previsión Social, Asunción, Paraguay Universidad Nacional de Asunción, Facultad de Medicina, Departamento de Reumatología, San Lorenzo, Paraguay
Palabras clave: Vasculitis Sistémicas, clasificación, Púrpura de Henoch-Schönlein, Vasculitis IgA

Resumen

La púrpura de Henoch-Schönlein (PHS), también llamada vasculitis IgA, es la vasculitis sistémica más común en la infancia, aunque también se presenta en adultos. El rasgo patológico característico de esta vasculitis es el depósito de complejos inmunes que contiene IgA en las paredes vasculares de los órganos afectados. Esta enfermedad se caracteriza por presentar púrpura palpable, artritis/artralgias, dolor abdominal, y enfermedad renal, pudiendo además afectar otros órganos. El laboratorio no certifica el diagnóstico, el cual se realiza por criterios de clasificación, habiendo descartado otras patologías. Presentamos esta revisión por la importancia del diagnóstico adecuado y temprano, a fin de realizar el tratamiento oportuno en caso de afección de un órgano vital.

Citas

(1) Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65(1):1–11.

(2) Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. I ncidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002;360:1197–1202.

(3) Rook A. William Heberden’s cases of anaphylactoid purpura. Arch. Dis. Child. 1958;33:271.

(4) Schönlein JL. Allgemeine und Specielle Pathologie und Therapie, V ol. 2, 3rd edn. Wurzburg: Herisau, 1837;48.

(5) Henoch EH. Über eine eigenthümliche Form von Purpura. Berl. Klin. Wochenschr.1874;11:641–3.

(6) Gedalia A. Henoch-Schönlein purpura. Curr Rheumatol Rep 2004;6:195–202.

(7) Dolezalova P, Telekesova P, Nemcova D, Hoza J. Incidence of vasculitis in children in the Czech Republic: 2-year prospective epidemiology survey. J Rheumatol 2004;31:2295–2299.

(8) Aalberse J, Dolman K, Ramnath G, Pereira RR, Davin JC. Henoch Schönlein purpura in children: an epidemiological study among Dutch paediatricians on incidence and diagnostic criteria. Ann Rheum Dis 2007;66:1648–1650.

(9) Yang YH, Hung CF, Hsu CR, Wang LC, Chuang YH, Lin YT, Chiang BL. A nationwide survey on epidemiological characteristics of childhood Henoch-Schönlein purpura in Taiwan. Rheumatology (Oxford) 2005;44:618–622.

(10) Cáceres-Mosquera J, Fuentes-Velasco Y, Romero-Navarro B. Púrpura de Henoch-Schönlein. Reporte de 105 pacientes pediátricos. Bol Med Hosp Infant Mex 2006;63(sept-oct):314-321.

(11) Hocevar A, Rotar Z, Ostrovsnik. Incidence of IgA Vasculitis in the adult Slovenian population. Dermatol 2014; 171:524.

(12) Calvo-Río V, Loricera J, Mata C. Henoche-Schonlein purpura in northern Spain: clinical spect disease in 417 patients from a single center. Medicine (Baltimore) 2024;93:106.

(13) Kang Y, Parks Js, Ha YJ. Differences in clinical manifestation and outcome between adult and child patients with Henoch-Schonlein purpura. J Korean Med Sci 2014; 29:198

(14) Trapani S, Micheli A, Grisolia F. Henoch Schonlein purpura inchildhood: epidemiologcal and clinical analysis of 150 cases over 5-year period. Semin Arthritis Rheum 2005;35:143.

(15) Calviño MC, Llorca J, García-Porrúa C. Henoch-Schoenlein purpura in children from northwestern Spain: a 20year epidemiologic and clinical study. Medicine (Baltimore) 2001;80:279.

(16) Piram M, Mahr A. Epidemiology os inmunoglobulin A vasculitis (Henoch-Schonlein) current state of knowledge. Current Opinion R heumatol 2013;25:171.

(17) Brogan PA. What’s new in the aetiopathogenesis of vasculitis? Pediatr Nephrol 2007;22:1083–1094.

(18) Watanabe T. Henoch-Schönlein purpura following influenza vaccinations during the pandemic of influenza A (H1N1).Pediatr. N ephrol.2011;25: 795–8.

(19) Amoli MM, Thomson W, Hajeer AH, et al. Interleukin 1 receptor antagonist gene polymorphism is associated with severe renal involvement and renal sequelae in Henoch-Schönlein purpura. J Rheumatol 2002;29:1404–1407.

(20) Gershoni-Baruch R, Broza Y, Brik R. Prevalence and significance of mutations in the familial Mediterranean fever gene in Henoch-Schönlein purpura. J Pediatr 2003;143:658–661.

(21) Kiryluk K, Moldoveanu Z, Sanders JTet al. Aberrant glycosylation of I gA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritis.Kidney Int.2011;80:79–87.

(22) Sanders JT, Wyatt RJ. IgA nephropathy and Henoch Schönlein purpura nephritis.Curr. Opin. Pediatr.2008;20:163–70.

(23) Kerr MA. The structure and function of human IgA.Biochem. J.1990;271:285–96.

(24) Allen AC, Willis FR, Beattie TJet al. Abnormal IgA glycosylation in Henoch-Schönlein purpura restricted to patients with clinical nephritis. Nephrol. Dial. Transplant.1998;13:930–4.

(25) Novak J, Julian BA, Tomana Met al. IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy.Semin. Nephrol.2008;28:78–87.

(26) Belman AL, Leicher CR, Mosché SL, Mezey AP. Neurologic manifestatation of Schoenlein-Henoch purpura: report of three cases and review of the literatura. Pediatrics 1985;75:687.

(27) Dinler G, Bek K, Acikgoz Y, Kalayci AG. Acute pancreatitis as a presenting feature of Henoch-Schonlein purpura. Turk J Pediatr 2010;52(2):191-193.

(28) Koskimies O, Rapola J, Savilahti E, Vilska J. Renal involvement in Henoch Schönlein purpura. Acta Pediatr Scand 1974;63:357–363.

(29) Stewart M, Savage JM, Bell B, McCord B. Long term renal prognosis of Henoch-Schönlein purpura in an unselected childhood population. Eur J Pediatr 1988;147:113–115.

(30) Jauhola O, Ronkainen J, Koskimies O, et al. Renal manifestations of Henoch–Schönlein purpura in a 6-month prospective study of 223 children. Arch Dis Child 2010;95:877–882.

(31) Webb NJA, Brogan PA, Baildam EM. Renal manifestations of systemic disorders. In: Webb N, Postlethwaite R (eds) Clinical paediatric nephrology. Oxford University Press, Oxford, 2003;381–403.

(32) Blanco R, Martínez-Taboada VM, Rodríguez-Valverde V, et al. Henoch-Schönlein purpura in adulthood and childhood: two different expressions of the same syndrome. Arthritis Rheum 1997; 40:859.

(33) Rauta V, Tornroth T, Gronhagen-Riska C. Henoch-Schoenlein nephritis inadults features and outcomes in Finnish patients. Clin Nephrol 2002, 58:1-8.

(34) Rostoker G. Schonlein-Henoch purpura in children and adults: diagnosis, pathophysiology and management. Biodrugs 2001; 15: 99138.

(35) Saulsbury FT. Epidemiology of Henoch-Schoenlein purpura. Cleve Clin J Med 2002:69 Suppl 2:SII87.

(36) Lin JJ, Stewart CL, Kaskel FJ, Fine RN. IgG and IgA classes of antineutrophil cytoplasmic autoantibodies in a 13-yearold girl with recurrent Henoch-Schönlein purpura. Pediatr Neph rol 1993;7:143–146.

(37) Reamy BV, Williams PM. Henoch-Schönlein Purpura . Am Fam Physician 2009; 80(7): 697-704.

(38) Gunasekaran TS, Berman J, Gonzalez M. Duodenojejunitis: is it idiopathic or is it Henoch-Schönlein purpura without the purpura? J Pediatr Gastroenterol Nutr 2000;30:22–28.

(39) Kamitsuji H, Tani K, Yasui M. Activity of blood coagulation factor XIII as a prognostic indicator in patients with Henoch-Schönlein purpura. Efficacy of factor XIII substitution. Eur J Pediatr 1987;146:519–523.

(40) Kawasaki K, Komura H, Nakahara Y, et al. Factor XIII in Henoch-Schönlein purpura with isolated gastrointestinal symptoms. Pediatr Int 2006;48:413–415.

(41) Lau KK, Wyatt RJ, Moldoveanu Z, et al. Serum levels of galactosedeficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura. Pediatr Nephrol 2007;22:2067–2072.

(42) Shin JI, Kim JH, Lee JS. The diagnostic value of IgA deposition in Henoch-Schönlein purpura. Pediatr Dermatol 2008;25:140–141.

(43) Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006;65:936–941.

(44) Ruperto N, Ozen S, Pistorio A, et al. EULAR/PRINTO/PRES criteria for Henoch- Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. Ann Rheum Dis 2010;69:790-797.

(45) Ozen S, Pistorio A, Lusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch- Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 2010;69:798-806.

(46) Rees L, Webb NJA, Brogan PA. Vasculitis. In: Rees L, Webb NJA, Brogan PA (eds) Paediatric nephrology (Oxford Handbook). Oxford University Press, Oxford, 2007:310–313.

(47) Meadow SR, Glasgow EF, White RHR. Schönlein–Henoch nephritis. Q. J. Med. 1972; 41: 241–58.

(48) Carlson JA, Chen KR. Cutaneous vasculitis update: small vessel neutrophilic vasculitis syndromes. Am J Dermatopathol 2006;28:486–506.

(49) Eshach Adiv O, Butbul Y, Nutenko I, Brik R. Atypical Henoch-Schonlein Purpura: A Forerunner of Familial Mediterranean Fever.I MAJ 2011;13:209–211.

(50) Huber AM, King J, McLaine P, et al. A randomized, placebocontrolled trial of prednisone in early Henoch-Schönlein purpura [ISRCTN85109383]. BMC Med 2004;2:7.

(51) Ronkainen J, Koskimies O, Ala-Houhala M, et al. Early prednisone therapy in Henoch-Schönlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr 2006;149:241–247.

(52) Zaffanello M, Fanos V. Treatment-based literature of Henoch-Schönlein purpura nephritis in childhood. Pediatr Nephrol 2009;24:1901–1911.

(53) Davin JC, Coppo R. Pitfalls in recommending evidence-based guidelines for a protean disease like Henoch-Schonlein purpura nephritis. Pediatr Neprol 2013; 28:1897.

(54) Ronkainen J, Ala-Houhala M, AntikainenM, et al. Cyclosporine A (CSA) versus methylprednisolone pulses (MP) in the treatment of severe Henoch-Schonlein purpura. Pediatr Nephrol 2006; 21:1531.

(55) Shenoy M, Ognjanovic MV, Coulthard MG. Treating severe Henoch-Schonlein and IgA nephritis with plasmapheresis alone. Pediatr Nephrol 2007;22:1167–1171.

(56) Donnithorne KJ, Atkinson TP, Hinze CH, et al. Rituximab therapy for severe refractory chronic Henoch-Schonlein purpura. J Pediatr 2009; 155:136–139.

(57) Boyer EM, Turman M, O’Neil KM. Partial response to anakinra in lifethreatening Henoch-Schönlein purpura: case report. Pediatric Rheumatology 2011;9:21.

(58) Nast CC, Ward HJ, Koyle MA, Cohen AH. Recurrent Henoch-Schonlein purpura following renal transplantation. Am J Kidney Dis1987;9:39.

(59) Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schönlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 2005;90:916–920.

(60) Watson L, Richardson AR, Holt RC, et al. Henoch Schonlein Purpura – A 5-Year Review and Proposed Pathway. PLoS One. 2012;7(1):e29512.

(61) Ushiyima Y, Kawasaki Y, Kaneko M, et al. A case of Henoch-Schonlein purpura nephritis recurring after 3 years remission. Fukushima J Med Sci 2010;56(1):50-56.

(62) Ha TS, Lee JS. Scrotal involvement in childhood Henoch-Schönlein purpura. Acta Paediatr.2007;96:552–5.

(63) Vats KR, Vats A, Kim Yet al. Henoch-Schönlein purpura and pulmonary hemorrhage: a report and literature review. Pediatr. N ephrol.1999;13:530–4.

(64) Robson WL, Leung AK, Mathers MS. Renal colic due to Henoch-Schönlein purpura. J. S. C. Med. Assoc.1994;90:592–5.

Publicado
2017-06-27
Cómo citar
Morel, Z., & Cabrera-Villalba, S. (2017). Púrpura de Henoch-Schönlein. Revisión de la literatura. Revista Paraguaya De Reumatología, 3(1), 25-32. Recuperado a partir de http://revista.spr.org.py/index.php/spr/article/view/70
Sección
REVISIÓN